TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07757659: A Phase Id, Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Bridging Study To Evaluate The Pharmacokinetics, Safety, Tolerability, and Immunogenicity of XKH001 in Healthy Adult Caucasian Participants

Sponsor: Zhejiang Kanova Biopharmaceutical Co., LTD · Phase: PHASE1 · Area: IMMUNOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,090,820

Rescue Site Savings

+$3,354,780

Unlock Full NCT07757659 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07757659 Rescue Dossier →